3GINA Executive Committee.Global Strategy for asthma management and prevention 2004(update).http://www.ginasthma.org.
4Weiss KB,Sullivan SD.The health economies of asthma and rhinitis.I.Assessing the economic impact[J].J Allergy Clin Immunol,2001,107(1):3-8.
5Ramsay CM,Cowan J,Flannery E,et al.Brenehoproteetive and bronchodilator effects of single doses of(S)-salbutamol,(R)-salbutamol and racemic salbutamol in patients with bronchial asthma[J].Eur J Clin Pharmacol,1999,55(5):353-359.
6Pleskow WW,Nelsen HS,Schaefer K,et al.Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderateto-severe asthma[J].Allergy Asthma Proc,2004,25(6):429-436.
3Munoz Soto RB, Albores Medina A. Genetic polimorphisms and xcnobiotic exposure in infantile asthma. Gac Med Mex,2011,147 ( 1 ) :38-47.
4Walker DM. Update on epinephrine(adrenaline) for pediatric e- mergencies. Curr Opin Pediatr,2009,21 (3) :313-319.
5Medoff BD. Invasive and noninvasive ventilation in patients with asthma. Respir Care,2008,53 (6) :740-748.
6Slovis CM. 5-Step asthma approach : managing acute asthma in 5 steps or less. JEMS ,2006,28 (12) :64-72.
7Pleskow WW, Nelson HS, Sehaefer K, et al. Pairwise comparison of Levalbuterol versus raeemie albuterol in the treatment of mod- erate to severe asthma. Allergy Asthma Proc, 2008,25 ( 6 ) : 429- 436.
